Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene PLC (AIM: FGN)  said its unit CBD Technologies Ltd has entered into a collaborative agreement with Oregon State University under which it will provide professor Steven Strauss’ research group at the Forest Biotechnology department with a proprietary eucalyptus clone and a highly efficient eucalyptus transformation protocol.

The collaboration will facilitate rapid and efficient evaluation of genes for flowering control and other biosafety aspects of tree modification.

In addition CBD Tech plans to join the Tree Biosafety and Genomics Research Cooperative (TBGRC), an internationally recognised tree research consortium that has been working with forest industries on tree biotechnology for 15 years and which is directed by Professor Strauss.

Although eucalyptus is the most widely planted commercial plantation tree species for pulp and paper production in the world, this species is notoriously difficult to transform, FurturaGene said in a statement.

Thus, the supply of a proprietary clone and transformation method from the company to a public research institute, under appropriate material usage and confidentiality provisions, represents a significant contribution to accelerating public research and development in this species, it added.



Register here to be notified of future FGN Company articles
View full FGN profile

Futuragene Timeline

Related Articles

Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
Dendritic cells with T-lymphocytes
July 21 2016
With cases of skin cancer on the rise, Scancell's immunotherapy study data has come at the right time, but is it enough to offset the insecurity in the sector?

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.